Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 17/20 | 0.76 |
| ▸ | ROCK1 | Q13464 | 9/20 | 0.76 |
| ▸ | PRKACA | P17612 | 6/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
| ▸ | GSK3A | P49840 | 1/20 | 0.72 |
| ▸ | GSK3B | P49841 | 1/20 | 0.72 |
| ▸ | PRKX | P51817 | 1/20 | 0.72 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.72 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.72 |
| ▸ | PRKACG | P22612 | 5/20 | 0.69 |
| ▸ | PRKACB | P22694 | 5/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18685145 | 0.87 | ROCK2 (0.81) | ROCK2ROCK1PRKACAPRKACGPRKACB | |
| SCHEMBL15967941 | 0.86 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL15968065 | 0.86 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL3246002 | 0.86 | ROCK2 (0.72) | ROCK2ROCK1PRKACAPRKACGPRKACB | |
| SCHEMBL15968010 | 0.86 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL15968147 | 0.85 | ROCK2 (1.00) | ROCK2ROCK1PRKACAPRKACGPRKACB | |
| SCHEMBL3249431 | 0.85 | ROCK2 (1.00) | ROCK2ROCK1CYP2C9 | |
| SCHEMBL18685098 | 0.84 | ROCK2 (0.80) | ROCK2ROCK1PRKACAPRKACGPRKACB | |
| SCHEMBL17439838 | 0.84 | ROCK2 (1.00) | ROCK2ROCK1PRKACAPRKACGPRKACB | |
| SCHEMBL17439778 | 0.84 | ROCK2 (1.00) | ROCK2ROCK1PRKACAPRKACGPRKACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1713775-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-08-12 | — | — | EP | claimed |
| US-20080275062-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-11-06 | — | — | US | claimed |
| EP-1713775-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-25 | — | — | EP | claimed |
| WO-2005074643-A2 | BENZAMIDE COMPOUNDS USEFUL AS ROCK INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-18 | — | — | WO | claimed |
| EP-1713775-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20080275062-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-11-06 | — | — | US | disclosed |
| US-20080275062-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-11-06 | — | — | US | disclosed |
| US-20080275062-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-11-06 | — | — | US | disclosed |
| EP-1713775-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005074643-A2 | BENZAMIDE COMPOUNDS USEFUL AS ROCK INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275062-A1 | Chemical Compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, CBR3 | ROCK2 3638/4885ROCK1 2695/4885PRKACA 3762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.